First Choice Neurology

Biogen

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients

Biogen is providing its new Alzheimer’s drug Aduhelm free to some patients because of slow reviews by Medicare. There is a division among doctors about whether Aduhelm, also known as aducanumab, the $56,000-a-year drug helps patients. There is also uncertainty about reimbursement from Medicare. Aduhelm was approved by the U.S. Food and Drug Administration (FDA) …

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients Read More »

Dr. Brad Herskowitz Participates in SAGE-324 Phase 2 KINETIC Study

Last week Sage Therapeutics, Inc. and Biogen Inc. announced the results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor. Essential Tremor (ET) is a movement disorder affecting an estimated 6.4 million Americans. For ET patients, uncontrollable shaking of the hands, head, voice, or legs creates difficulty eating, …

Dr. Brad Herskowitz Participates in SAGE-324 Phase 2 KINETIC Study Read More »

Translate »